Founded in 2000 in Barcelona, Spain, Oryzon Genomics, S.A. (ISIN Code: ES0167733015) (“Oryzon”) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company leverages epigenetics to discover and develop innovative personalized therapeutics for diseases with a strong unmet medical need, with a particular focus in oncology and CNS diseases.
Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds in clinical trials: iadademstat and vafidemstat, both currently in Phase II. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases.
Oryzon has offices in Spain and the United States.
